PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known

Application Number 10/662,606

Filing Date September 15, 2003

First Named Inventor Christiane Yoakim et al

Art Unit 1624

Examiner Name To be assigned COLEMAN

(Use as many sheets as necessary)

To be a sheet 1 of 2 Attorney Docket Number 13/096

Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where
Initials*	No.1	Number-Kind Code <sup>2 (# known)</sup>	MM-DD-YYYY	Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			
terment a register		US-			
		US-			
		US-			
		US-	··· <del>··································</del>		
		US-			······································
		US-			
		US-	-		
		US-			· · · · · · · · · · · · · · · · · · ·
		US-	· · · · · · · · · · · · · · · · · · ·		
		US-			

	FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	٠,			
madis	110.	Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>3</sup> (if known)	MAPOOFITT	Applicant of Cited Document	or Relevant Figures Appear				
BC		EP 0767172	04/09/1997	ARCO Chemical Tech					
BC		WO 02/076982	10/3/2002	Boehringer Ingelheim (Canada) LTD					
BC		WO 03/011862	02/13/2003	Boehringer Ingelheim (Canada) LTD.	:				
BC		EP 0791594	08/27/1997	Boehringer Ingelheim Pharmacueticals, Inc.	1 00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0				

Examiner Signature	Brenda	Colono	Date Considered	Oct. 27,2005

'EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patient Documents at <a href="www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patient documents, the indication of the year of the reign of the Emperor must precede the serial number of the patient document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 06/30/2008. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute fo	r form 14498/PTO			Complete If Known		
				Application Number	10/662,606	
INFO	RMATION DI	SCLOS	SURE	Filing Date	September 15, 2003	
STAT	STATEMENT BY APPLICANT			First Named Inventor	Christiane Yoakim et al	
				Art Unit	1624	
	(Use as many sheets as	necessary)		Examiner Name	To be assigned COLEMAN	
Sheet	2	of	2	Attorney Docket Number	13/096	
Sneet	] 2	or	2	Attorney Docket Number	13/096	

		NON PATENT LITERATURE DOCUMENTS	NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²						
BU		NICHOLAS K. TERRETT ET AL; Imidazo[2',3':6,5]Dipyrido[3,2-b:2',3'-e] - 1,4 - Diazepines: Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors with Greater Enzyme Affinity than Nevirapine; Bioorganic & Medicinal Chemistry Letters Vol. 2 No. 12 page 1745-1750 (1992); Pergamon Press							
BC		Copy of International Search Report Reference #PCT/CA 03/01410 및 교육니							
	************								
			***************************************						
		·							
•••••••••••••••••••••••••••••••••••••••									

	<b>D</b> (	0 )		1 2= 2.75
Examiner Signature	Brenda	Coleman	Date Considered	02.24,2005

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered, include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.